Sridhar VS - Search Results

1

SGLT2 inhibition, glucose transport and peritoneal dialysis: Finding the sweet spot.

Sridhar VS, Fraser DJ. Sridhar VS, et al. Perit Dial Int. 2023 Mar;43(2):115-118. doi: 10.1177/08968608231161178. Perit Dial Int. 2023. PMID: 37013683 No abstract available.

2

The Sweet Science of Glucose Transport.

Sridhar VS, Bargman JM. Sridhar VS, et al. J Am Soc Nephrol. 2022 Oct;33(10):1803-1804. doi: 10.1681/ASN.2022070841. Epub 2022 Sep 9. J Am Soc Nephrol. 2022. PMID: 36630519 Free PMC article. No abstract available.

3

What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?

Sridhar VS, Rahman HU, Cherney DZI. Sridhar VS, et al. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:55-68. doi: 10.1111/dom.13965. Diabetes Obes Metab. 2020. PMID: 32267075 Review.

4

We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury.

Sridhar VS, Tuttle KR, Cherney DZI. Sridhar VS, et al. Am J Kidney Dis. 2020 Oct;76(4):454-456. doi: 10.1053/j.ajkd.2020.05.014. Epub 2020 Jul 22. Am J Kidney Dis. 2020. PMID: 32712014 No abstract available.

5

Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease.

Almaimani M, Sridhar VS, Cherney DZI. Almaimani M, et al. Among authors: sridhar vs. Curr Opin Nephrol Hypertens. 2021 Sep 1;30(5):474-481. doi: 10.1097/MNH.0000000000000724. Curr Opin Nephrol Hypertens. 2021. PMID: 34074889 Review.

6

Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Sridhar VS, Ambinathan JPN, Gillard P, Mathieu C, Cherney DZI, Lytvyn Y, Singh SK. Sridhar VS, et al. Transplantation. 2022 Apr 1;106(4):734-748. doi: 10.1097/TP.0000000000003919. Transplantation. 2022. PMID: 34381005 Review.

7

SGLT2 Inhibitors: The Sweet Success for Kidneys.

Dharia A, Khan A, Sridhar VS, Cherney DZI. Dharia A, et al. Among authors: sridhar vs. Annu Rev Med. 2023 Jan 27;74:369-384. doi: 10.1146/annurev-med-042921-102135. Annu Rev Med. 2023. PMID: 36706745 Free article. Review.

8

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.

Sridhar VS, Dubrofsky L, Boulet J, Cherney DZ. Sridhar VS, et al. J Bras Nefrol. 2020 Oct-Dec;42(4):467-477. doi: 10.1590/2175-8239-JBN-2020-0100. J Bras Nefrol. 2020. PMID: 32926067 Free PMC article. Review.

9

SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series.

Škrtić M, Cherney DZI, Sridhar VS, Chan CTM, Kitchlu A. Škrtić M, et al. Among authors: sridhar vs. Can J Kidney Health Dis. 2021 Dec 14;8:20543581211065528. doi: 10.1177/20543581211065528. eCollection 2021. Can J Kidney Health Dis. 2021. PMID: 34925865 Free PMC article.

10

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Liu H, Sridhar VS, Perkins BA, Rosenstock J, Cherney DZI. Liu H, et al. Among authors: sridhar vs. Curr Diab Rep. 2022 Jul;22(7):317-332. doi: 10.1007/s11892-022-01471-2. Epub 2022 May 28. Curr Diab Rep. 2022. PMID: 35633439 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page